Immuneering Corp Stock Performance
| IMRX Stock | USD 1.80 0.15 9.09% |
The company retains a Market Volatility (i.e., Beta) of 0.84, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Immuneering Corp's returns are expected to increase less than the market. However, during the bear market, the loss of holding Immuneering Corp is expected to be smaller as well. At this point, Immuneering Corp has a negative expected return of -0.25%. Please make sure to check out Immuneering Corp's jensen alpha, skewness, as well as the relationship between the Skewness and day typical price , to decide if Immuneering Corp performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Immuneering Corp has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
1 | Acquisition by Keating Laurie of 23485 shares of Immuneering Corp at 2.2 subject to Rule 16b-3 | 12/31/2024 |
2 | Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase ... | 01/07/2025 |
3 | Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer | 01/13/2025 |
4 | Immuneering Corporation Shares Jump 55 percent Following Breakthrough Pancreatic Cancer Trial Results - HPBL | 01/27/2025 |
5 | Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference | 02/03/2025 |
6 | Acquisition by Bookman Michael of 110000 shares of Immuneering Corp at 1.91 subject to Rule 16b-3 | 02/05/2025 |
7 | Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo | 02/06/2025 |
8 | Acquisition by Schall Thomas J. of 8588 shares of Immuneering Corp at 1.54 subject to Rule 16b-3 | 02/27/2025 |
9 | Immuneering Slides As Insider Purchases Lose Another US186k | 03/05/2025 |
10 | Acquisition by Berman Ann E of 17614 shares of Immuneering Corp at 2.2 subject to Rule 16b-3 | 03/07/2025 |
11 | Acquisition by Brett Hall of 6211 shares of Immuneering Corp at 1.62 subject to Rule 16b-3 | 03/12/2025 |
| Begin Period Cash Flow | 72.6 M |
Immuneering |
Immuneering Corp Relative Risk vs. Return Landscape
If you would invest 220.00 in Immuneering Corp on December 22, 2024 and sell it today you would lose (40.00) from holding Immuneering Corp or give up 18.18% of portfolio value over 90 days. Immuneering Corp is currently does not generate positive expected returns and assumes 3.9465% risk (volatility on return distribution) over the 90 days horizon. In different words, 35% of stocks are less volatile than Immuneering, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Immuneering Corp Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Immuneering Corp's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Immuneering Corp, and traders can use it to determine the average amount a Immuneering Corp's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0646
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | IMRX |
Estimated Market Risk
| 3.95 actual daily | 35 65% of assets are more volatile |
Expected Return
| -0.25 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.06 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Immuneering Corp is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Immuneering Corp by adding Immuneering Corp to a well-diversified portfolio.
Immuneering Corp Fundamentals Growth
Immuneering Stock prices reflect investors' perceptions of the future prospects and financial health of Immuneering Corp, and Immuneering Corp fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Immuneering Stock performance.
| Return On Equity | -0.72 | ||||
| Return On Asset | -0.42 | ||||
| Current Valuation | 4.82 M | ||||
| Shares Outstanding | 31.05 M | ||||
| Price To Book | 0.89 X | ||||
| Price To Sales | 563.62 X | ||||
| Revenue | 455 | ||||
| Gross Profit | 158.83 K | ||||
| EBITDA | (58.06 M) | ||||
| Net Income | (53.47 M) | ||||
| Cash And Equivalents | 128.1 M | ||||
| Cash Per Share | 4.85 X | ||||
| Total Debt | 4.46 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 33.99 X | ||||
| Book Value Per Share | 1.86 X | ||||
| Cash Flow From Operations | (48.97 M) | ||||
| Earnings Per Share | (1.97) X | ||||
| Market Capitalization | 51.23 M | ||||
| Total Asset | 102.58 M | ||||
| Retained Earnings | (163.26 M) | ||||
| Working Capital | 81.24 M | ||||
About Immuneering Corp Performance
Evaluating Immuneering Corp's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Immuneering Corp has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Immuneering Corp has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.34) | (1.27) | |
| Return On Capital Employed | (1.42) | (1.35) | |
| Return On Assets | (1.16) | (1.22) | |
| Return On Equity | (1.47) | (1.40) |
Things to note about Immuneering Corp performance evaluation
Checking the ongoing alerts about Immuneering Corp for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Immuneering Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Immuneering Corp generated a negative expected return over the last 90 days | |
| Immuneering Corp may become a speculative penny stock | |
| Immuneering Corp has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 455. Net Loss for the year was (53.47 M) with profit before overhead, payroll, taxes, and interest of 158.83 K. | |
| Immuneering Corp currently holds about 128.1 M in cash with (48.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.85, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Immuneering Corp has a frail financial position based on the latest SEC disclosures | |
| Roughly 28.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Brett Hall of 6211 shares of Immuneering Corp at 1.62 subject to Rule 16b-3 |
- Analyzing Immuneering Corp's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Immuneering Corp's stock is overvalued or undervalued compared to its peers.
- Examining Immuneering Corp's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Immuneering Corp's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Immuneering Corp's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Immuneering Corp's stock. These opinions can provide insight into Immuneering Corp's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Immuneering Stock Analysis
When running Immuneering Corp's price analysis, check to measure Immuneering Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immuneering Corp is operating at the current time. Most of Immuneering Corp's value examination focuses on studying past and present price action to predict the probability of Immuneering Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immuneering Corp's price. Additionally, you may evaluate how the addition of Immuneering Corp to your portfolios can decrease your overall portfolio volatility.